{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:13:55Z","timestamp":1787984035352,"version":"build-2784847793"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Enthesitis is a hallmark of spondyloarthritis (SpA) with a substantial impact on quality of life. Reports of treatment effectiveness across individual enthesitis sites in real-world patients with axial SpA (axSpA) are limited. We investigated the evolution of enthesitis following tumor necrosis factor inhibitor (TNFi) initiation in axSpA patients, both cumulatively and at specific axial and peripheral sites.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>AxSpA patients in the Swiss Clinical Quality Management Registry were included if they initiated a TNFi, had an available Maastricht Ankylosing Spondylitis Enthesitis Score, modified to include the plantar fascia (mMASES, 0\u201315), at start of treatment and after 6 and\/or 12 months and \u226512 months follow-up. Logistic regression models were utilized to analyze explanatory variables for enthesitis resolution.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 1668 TNFi treatment courses (TCs) were included, of which 1117 (67%) had active enthesitis at baseline. Reduction in mMASES at the 6- and 12-month timepoints was experienced in 72% and 70% of TCs, respectively. Enthesitis resolution at 6\/12 months occurred in 37.9%\/43.0% of all TNFi TCs and 40.7%\/50.9% of first TNFi TCs. At 6 months, a significant reduction in the frequency of enthesitis was observed at all sites, except for the Achilles tendon and plantar fascia among first TNFi TCs, while at 12 months, reduction was significant at all sites in both TC groups. Enthesitis resolved in 60.3\u201377% across anatomical sites, while new incident enthesitis occurred in 4.0\u201313.5% of all TNFi TCs at 12 months. Both baseline and new-incident enthesitis occurred most frequently at the posterior superior iliac spine and the fifth lumbar spinous process. Younger age and lower mMASES at baseline were predictors of complete enthesitis resolution, while female sex and second- or later-line TNFi treatment were associated with persistence of enthesitis at 12 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In real-world axSpA patients treated with a TNFi, enthesitis improved in the majority of patients across all anatomical sites. Significant improvement at the Achilles and plantar fascia entheses was observed only at 12 months. Complete and site-specific enthesitis resolution occurred in \u226540% and \u226560% of TCs evaluated at 12 months, with a low incidence of new site-specific enthesitis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Not applicable.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02534-7","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T05:50:10Z","timestamp":1623217810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Site-specific resolution of enthesitis in patients with axial spondyloarthritis treated with tumor necrosis factor inhibitors"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6326-1764","authenticated-orcid":false,"given":"Michael J.","family":"Nissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruediger B.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Zueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Ganz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almut","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Papagiannoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"H\u00fcgle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"issue":"5","key":"2534_CR1","doi-asserted-by":"publisher","first-page":"e12913","DOI":"10.1111\/eci.12913","volume":"48","author":"A de Koning","year":"2018","unstructured":"de Koning A, Schoones JW, van der Heijde D, van Gaalen FA. Pathophysiology of axial spondyloarthritis: consensus and controversies. Eur J Clin Invest. 2018;48(5):e12913. https:\/\/doi.org\/10.1111\/eci.12913.","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"2534_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","volume":"23","author":"V Strand","year":"2017","unstructured":"Strand V, Singh JA. Patient burden of axial spondyloarthritis. J Clin Rheumatol. 2017;23(7):383\u201391. https:\/\/doi.org\/10.1097\/RHU.0000000000000589.","journal-title":"J Clin Rheumatol"},{"issue":"2","key":"2534_CR3","doi-asserted-by":"publisher","first-page":"e000825","DOI":"10.1136\/rmdopen-2018-000825","volume":"4","author":"D Poddubnyy","year":"2018","unstructured":"Poddubnyy D, Callhoff J, Spiller I, Listing J, Braun J, Sieper J, et al. Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care. RMD Open. 2018;4(2):e000825. https:\/\/doi.org\/10.1136\/rmdopen-2018-000825.","journal-title":"RMD Open"},{"issue":"1","key":"2534_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/1759720X12468658","volume":"5","author":"D Poddubnyy","year":"2013","unstructured":"Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskel Dis. 2013;5(1):45\u201354. https:\/\/doi.org\/10.1177\/1759720X12468658.","journal-title":"Ther Adv Musculoskel Dis"},{"issue":"5","key":"2534_CR5","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3899\/jrheum.081015","volume":"36","author":"JA Singh","year":"2009","unstructured":"Singh JA, Strand V. Spondyloarthritis is associated with poor function and physical health-related quality of life. J Rheumatol. 2009;36(5):1012\u201320. https:\/\/doi.org\/10.3899\/jrheum.081015.","journal-title":"J Rheumatol"},{"issue":"1","key":"2534_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13075-019-1826-x","volume":"21","author":"HHL Tsang","year":"2019","unstructured":"Tsang HHL, Cheung JPY, Wong CKH, Cheung PWH, Lau CS, Chung HY. Psychometric validation of the EuroQoL 5-dimension (EQ-5D) questionnaire in patients with spondyloarthritis. Arthritis Res Ther. 2019;21(1):41. https:\/\/doi.org\/10.1186\/s13075-019-1826-x.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2534_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12891-017-1693-z","volume":"18","author":"G Rohde","year":"2017","unstructured":"Rohde G, Berg KH, Proven A, Haugeberg G. The relationship between demographic- and disease-related variables and health-related quality of life in patients with axial spondyloarthritis. BMC Musculoskelet Disord. 2017;18(1):328. https:\/\/doi.org\/10.1186\/s12891-017-1693-z.","journal-title":"BMC Musculoskelet Disord"},{"key":"2534_CR8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2147\/PPA.S162420","volume":"12","author":"JC Torre-Alonso","year":"2018","unstructured":"Torre-Alonso JC, Queiro R, Comellas M, Lizan L, Blanch C. Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature. Patient Prefer Adherence. 2018;12:733\u201347. https:\/\/doi.org\/10.2147\/PPA.S162420.","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"2534_CR9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jbspin.2009.03.005","volume":"76","author":"Y Turan","year":"2009","unstructured":"Turan Y, Duruoz MT, Cerrahoglu L. Relationship between enthesitis, clinical parameters and quality of life in spondyloarthritis. Joint Bone Spine. 2009;76(6):642\u20137. https:\/\/doi.org\/10.1016\/j.jbspin.2009.03.005.","journal-title":"Joint Bone Spine"},{"issue":"7","key":"2534_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11926-018-0751-3","volume":"20","author":"A Watad","year":"2018","unstructured":"Watad A, Cuthbert RJ, Amital H, McGonagle D. Enthesitis: much more than focal insertion point inflammation. Curr Rheumatol Rep. 2018;20(7):41. https:\/\/doi.org\/10.1007\/s11926-018-0751-3.","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"2534_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/art.39458","volume":"68","author":"AS Kehl","year":"2016","unstructured":"Kehl AS, Corr M, Weisman MH. Review: Enthesitis: new insights into pathogenesis, diagnostic modalities, and teatment. Arthritis Rheumatol. 2016;68(2):312\u201322.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"2534_CR12","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1136\/ard.2007.070243","volume":"66","author":"I Eshed","year":"2007","unstructured":"Eshed I, Bollow M, McGonagle DG, Tan AL, Althoff CE, Asbach P, et al. MRI of enthesitis of the appendicular skeleton in spondyloarthritis. Ann Rheum Dis. 2007;66(12):1553\u20139. https:\/\/doi.org\/10.1136\/ard.2007.070243.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2534_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1136\/annrheumdis-2013-203643","volume":"73","author":"P Jacques","year":"2014","unstructured":"Jacques P, Lambrecht S, Verheugen E, Pauwels E, Kollias G, Armaka M, et al. Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis. 2014;73(2):437\u201345. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203643.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2534_CR14","first-page":"2155","volume":"28","author":"D McGonagle","year":"2001","unstructured":"McGonagle D, Stockwin L, Isaacs J, Emery P. An enthesitis based model for the pathogenesis of spondyloarthropathy. additive effects of microbial adjuvant and biomechanical factors at disease sites. J Rheumatol. 2001;28(10):2155\u20139.","journal-title":"J Rheumatol"},{"issue":"6","key":"2534_CR15","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770.","journal-title":"Ann Rheum Dis"},{"issue":"suppl_6","key":"2534_CR16","doi-asserted-by":"publisher","first-page":"vi10","DOI":"10.1093\/rheumatology\/key217","volume":"57","author":"B Noureldin","year":"2018","unstructured":"Noureldin B, Barkham N. The current standard of care and the unmet needs for axial spondyloarthritis. Rheumatology (Oxford). 2018;57(suppl_6):vi10\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2534_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13075-019-1849-3","volume":"21","author":"B Hernandez-Breijo","year":"2019","unstructured":"Hernandez-Breijo B, Plasencia-Rodriguez C, Navarro-Compan V, Martinez-Feito A, Jochems A, Kneepkens EL, et al. Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. Arthritis Res Ther. 2019;21(1):66. https:\/\/doi.org\/10.1186\/s13075-019-1849-3.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"2534_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3899\/jrheum.160387","volume":"44","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Van den Bosch F, Sieper J, Xia Y, Pangan AL, Song IH. Performance of 3 enthesitis indices in patients with peripheral spondyloarthritis during treatment with adalimumab. J Rheumatol. 2017;44(5):599\u2013608. https:\/\/doi.org\/10.3899\/jrheum.160387.","journal-title":"J Rheumatol"},{"issue":"8","key":"2534_CR19","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/art.38721","volume":"66","author":"M Dougados","year":"2014","unstructured":"Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014;66(8):2091\u2013102. https:\/\/doi.org\/10.1002\/art.38721.","journal-title":"Arthritis Rheumatol"},{"issue":"9313","key":"2534_CR20","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359(9313):1187\u201393. https:\/\/doi.org\/10.1016\/S0140-6736(02)08215-6.","journal-title":"Lancet"},{"issue":"10","key":"2534_CR21","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/art.39257","volume":"67","author":"J Sieper","year":"2015","unstructured":"Sieper J, van der Heijde D, Dougados M, Maksymowych WP, Scott BB, Boice JA, et al. A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2015;67(10):2702\u201312. https:\/\/doi.org\/10.1002\/art.39257.","journal-title":"Arthritis Rheumatol"},{"key":"2534_CR22","doi-asserted-by":"crossref","unstructured":"van der Heijde D, Dougados M, Landewe R, Sieper J, Maksymowych WP, Rudwaleit M, Van den Bosch F, Braun J, Mease PJ, Kivitz AJ et al: Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA. Rheumatology (Oxford) 2017:[Epub ahead of print].","DOI":"10.1093\/rheumatology\/kex174"},{"issue":"2","key":"2534_CR23","doi-asserted-by":"publisher","first-page":"R43","DOI":"10.1186\/ar2953","volume":"12","author":"M Rudwaleit","year":"2010","unstructured":"Rudwaleit M, Claudepierre P, Kron M, Kary S, Wong R, Kupper H. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res Ther. 2010;12(2):R43. https:\/\/doi.org\/10.1186\/ar2953.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2534_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study G: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582\u201391. https:\/\/doi.org\/10.1002\/art.20852.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2534_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/rheumatology\/kes251","volume":"52","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Braun J, Deodhar A, Inman RD, Xu S, Mack ME, et al. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). Rheumatology (Oxford). 2013;52(2):321\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/kes251.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"2534_CR26","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.38140","volume":"65","author":"A Ciurea","year":"2013","unstructured":"Ciurea A, Scherer A, Exer P, Bernhard J, Dudler J, Beyeler B, et al. Tumor necrosis factor alpha inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum. 2013;65(12):3096\u2013106. https:\/\/doi.org\/10.1002\/art.38140.","journal-title":"Arthritis Rheum"},{"key":"2534_CR27","unstructured":"About Us: The basis for successful therapy. https:\/\/www.scqm.ch\/en\/ueber-uns\/"},{"issue":"suppl 2","key":"2534_CR28","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(suppl 2):ii1\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2534_CR29","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1586\/1744666X.2014.943663","volume":"10","author":"M Her","year":"2014","unstructured":"Her M, Kavanaugh A. A review of disease activity measures for psoriatic arthritis: what is the best approach? Expert Rev Clin Immunol. 2014;10(9):1241\u201354. https:\/\/doi.org\/10.1586\/1744666X.2014.943663.","journal-title":"Expert Rev Clin Immunol"},{"key":"2534_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/OARRR.S179472","volume":"10","author":"W Hartung","year":"2018","unstructured":"Hartung W, Nigg A, Strunk J, Wolff B. Clinical assessment and ultrasonography in the follow-up of enthesitis in patients with spondyloarthritis: a multicenter ultrasound study in daily clinical practice. Open Access Rheumatol. 2018;10:161\u20139. https:\/\/doi.org\/10.2147\/OARRR.S179472.","journal-title":"Open Access Rheumatol"},{"issue":"9","key":"2534_CR31","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s10067-016-3353-3","volume":"35","author":"D Wendling","year":"2016","unstructured":"Wendling D, Prati C. Spondyloarthritis and fibromyalgia: interfering association or differential diagnosis? Clin Rheumatol. 2016;35(9):2141\u20133. https:\/\/doi.org\/10.1007\/s10067-016-3353-3.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2534_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/rheumatology\/kex079","volume":"57","author":"A Marchesoni","year":"2018","unstructured":"Marchesoni A, De Marco G, Merashli M, McKenna F, Tinazzi I, Marzo-Ortega H, et al. The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia. Rheumatology (Oxford). 2018;57(1):32\u201340. https:\/\/doi.org\/10.1093\/rheumatology\/kex079.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"2534_CR33","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/BOR.0000000000000388","volume":"29","author":"PJ Mease","year":"2017","unstructured":"Mease PJ. Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. Curr Opin Rheumatol. 2017;29(4):304\u201310. https:\/\/doi.org\/10.1097\/BOR.0000000000000388.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"2534_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s42358-019-0066-8","volume":"59","author":"PE Palominos","year":"2019","unstructured":"Palominos PE, de Campos APB, Ribeiro SLE, Xavier RM, Xavier JW, de Oliveira FB, et al. Correlation of enthesitis indices with disease activity and function in axial and peripheral spondyloarthritis: a cross-sectional study comparing MASES, SPARCC and LEI. Adv Rheumatol. 2019;59(1):23. https:\/\/doi.org\/10.1186\/s42358-019-0066-8.","journal-title":"Adv Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02534-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02534-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02534-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T05:51:24Z","timestamp":1623217884000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02534-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2534"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02534-7","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"19 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all patients before inclusion in the SCQM registry and a regional ethics committee (CER-VD, 2019-00278) provided approval for collection of patient data from the SCQM cohort.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"<i>MN<\/i> has received consulting fees from AbbVie, Celgene, Eli Lilly, Novartis, and Pfizer.<i>AC<\/i> has received consulting and\/or speaking fees from AbbVie, Celgene, MSD, Eli Lilly, Novartis, and Pfizer.<i>RM<\/i> has received honoraria and research support from AbbVie, Nordic, Pfizer, Janssen-Cilag, MSD, and Sanofi-Aventis.<i>PZ<\/i>, <i>MS<\/i>, and <i>FG<\/i> are employees of AbbVie Inc.<i>BM<\/i> has received honoraria from AbbVie, Celgene, Eli Lilly, Janssen-Cilag, Merck (MSD), Novartis, Pfizer, Roche, Sanofi-Aventis, and UCB.<i>AS<\/i> and <i>EP<\/i> have no conflicts to disclose.<i>TH<\/i> has received honoraria and research support from AbbVie, GSK, Eli Lilly, Novartis, Pfizer, Janssen-Cilag, MSD, and Sanofi-Aventis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"165"}}